Loading...
XKRX063160
Market cap86mUSD
Jan 09, Last price  
22,950.00KRW
1D
2.23%
1Q
-23.37%
Jan 2017
2.32%
Name

CKD Bio Corp

Chart & Performance

D1W1MN
XKRX:063160 chart
P/E
—
P/S
0.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.37%
Rev. gr., 5y
5.19%
Revenues
160.35b
+2.76%
66,409,841,00083,393,222,000106,553,579,000121,568,352,000110,527,721,450113,759,577,680100,370,797,420106,389,740,550106,690,657,800113,013,402,140118,187,072,160124,510,019,000137,184,188,550124,599,959,410142,238,418,400156,042,327,040160,352,778,354
Net income
-24.19b
L+44.84%
-3,273,392,0008,737,629,00016,183,929,00014,375,712,00010,920,596,3707,101,290,0801,657,448,850-1,105,050,1406,653,133,0009,434,614,7508,016,298,6207,956,187,16012,264,879,9606,207,398,430-6,576,601,340-16,702,615,620-24,192,519,640
CFO
-7.22b
L+125.42%
408,087,00010,689,037,00026,573,028,00023,887,459,00012,963,470,55022,900,061,37010,924,090,05011,222,959,39014,338,941,94015,500,000,86020,445,524,66015,535,533,73016,990,277,0004,824,020,040-5,882,180,150-3,204,562,880-7,223,883,844
Dividend
Dec 29, 2021100 KRW/sh
Earnings
Jan 27, 2025

Profile

CKD Bio Corp. manufactures and distributes drug substances based on fermentation, synthesis, and biotechnology in South Korea. It offers drug substances in the areas of antibiotic, ß-lactamase inhibitors, immunosuppressants, anticancer drugs, obesity treatment drugs, dry eye, antivirus, antituberculosis, antihyperlipidemics, and probiotics. The company also provides contract research and development, and manufacturing services for active pharmaceutical ingredients and intermediates, and probiotics. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.ckdbio.com/
IPO date
Dec 11, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
160,352,778
2.76%
156,042,327
9.70%
Cost of revenue
174,613,369
163,820,374
Unusual Expense (Income)
NOPBT
(14,260,591)
(7,778,046)
NOPBT Margin
Operating Taxes
(4,098)
(1,887,245)
Tax Rate
NOPAT
(14,256,492)
(5,890,801)
Net income
(24,192,520)
44.84%
(16,702,616)
153.97%
Dividends
(548,596)
Dividend yield
0.42%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
76,503,299
57,015,206
Long-term debt
72,133,718
84,162,321
Deferred revenue
Other long-term liabilities
1,697,436
1,171,986
Net debt
142,700,107
134,518,061
Cash flow
Cash from operating activities
(7,223,884)
(3,204,563)
CAPEX
(10,778,381)
(7,230,209)
Cash from investing activities
(1,195,570)
(20,546,514)
Cash from financing activities
7,402,421
24,959,279
FCF
(5,046,533)
(5,883,573)
Balance
Cash
3,699,770
12,724,497
Long term investments
2,237,140
(6,065,030)
Excess cash
Stockholders' equity
93,523,095
120,214,873
Invested Capital
271,648,591
287,896,838
ROIC
ROCE
EV
Common stock shares outstanding
5,486
5,486
Price
23,850.00
0.21%
23,800.00
-43.06%
Market cap
130,840,146
0.21%
130,565,872
-43.06%
EV
273,540,253
265,083,933
EBITDA
3,317,010
10,160,213
EV/EBITDA
82.47
26.09
Interest
4,988,555
2,938,333
Interest/NOPBT